Skip to main content
Top
Published in: Annals of Surgical Oncology 4/2009

Open Access 01-04-2009 | Hepatobiliary and Pancreatic Tumors

Pancreaticoduodenectomy and Vascular Resection: Persistent Controversy and Current Recommendations

Authors: Kathleen Christians, MD, Douglas B. Evans, MD

Published in: Annals of Surgical Oncology | Issue 4/2009

Login to get access

Excerpt

In this issue of the Journal, Giovanni and colleagues analyze 12 recent manuscripts which reported the outcome of patients with pancreatic cancer who required portal vein (PV) or superior mesenteric vein (SMV) resection at the time of pancreaticoduodenectomy (PD).1 They conclude that venous resection can be safely performed and should be considered in appropriately selected patients. Fortner first popularized vascular resection at the time of PD in 1973 when he proposed the use of “regional pancreatectomy.”2 However, this concept has remained controversial for the following reasons:
1.
Most physicians do not understand the difference between the historical experience with regional pancreatectomy and isolated tumor resection of the SMV, PV or superior mesenteric–portal vein (SMPV) confluence performed as part of a gross complete resection of the primary tumor. Vascular resection at the time of PD was initially performed in an attempt to improve survival duration by performing an en bloc resection of the pancreas and surrounding structures.2 This concept of regional pancreatectomy involved the systematic resection of major peripancreatic vascular structures together with wide soft tissue clearance. Contrary to the beliefs of Fortner and others, radical PD has not been demonstrated to confer a survival benefit.3,4 Most physicians and many surgeons assume that the negative experience with regional pancreatectomy also applies to patients with isolated tumor extension that involves a short segment of the SMV or PV.
 
2.
The addition of vascular resection and reconstruction to PD increases the complexity of the operation and is not something that all pancreatic surgeons feel capable of performing. This issue may be amplified by the limited experience of many surgeons with the technical aspects of vascular surgery and the potential for perioperative death and major morbidity that exists with pancreatic surgery for cancer.
 
3.
The published data which examines vascular resection as a prognostic factor for survival duration is of poor quality. The majority of such reports (including those analyzed by Giovanni and colleagues) did not contain a description of the process used to differentiate complete (R0/R1) from incomplete (R2) gross resections. Even in those patients who may have undergone a complete gross resection, most manuscripts failed to incorporate prospective standardized pathologic evaluation and reporting of the PD specimen to differentiate R0 from R1 resections. This is a critically important consideration because the intraoperative finding of venous adherence to the tumor is often unexpected and the surgeon may then attempt to separate the SMPV confluence from the pancreatic head. When this maneuver is unsuccessful, the surgeon is left with either a grossly positive margin or an inadvertent venotomy. Venous injury often results in uncontrolled hemorrhage and the necessity for rapid removal of the tumor without proper attention to the SMA dissection; it is easy to appreciate how such cases may result in an R2 resection. In patients with grossly incomplete resections, and without any form of preoperative therapy, it is likely that their poor survival is due to the persistent adenocarcinoma at the SMA or celiac origin, not the presence of a vascular reconstruction. In the absence of prospective evaluation of the SMA margin (performed by very few of the papers analyzed by Giovanni and colleagues), reports of venous resection during PD are impossible to interpret. Further, even if the SMA margin is assessed accurately, the pathologist cannot differentiate an R2 from an R1 resection; the surgeon’s operative note must state whether or not a gross complete resection was performed.5
 
Literature
1.
go back to reference Giovanni R, Paolo M, Niccolo P, et al. Does portal-superior mesenteric vein invasion still indicate irresectability for pancreatic carcinoma? Ann Surg Oncol. 2009. DOI:10.1245/s10434-008-0281-8. Giovanni R, Paolo M, Niccolo P, et al. Does portal-superior mesenteric vein invasion still indicate irresectability for pancreatic carcinoma? Ann Surg Oncol. 2009. DOI:10.​1245/​s10434-008-0281-8.
2.
go back to reference Fortner JG. Regional resection of cancer of the pancreas: a new surgical approach. Surgery. 1973;73:307–20.PubMed Fortner JG. Regional resection of cancer of the pancreas: a new surgical approach. Surgery. 1973;73:307–20.PubMed
3.
go back to reference Riall TS, Cameron JL, Lillemoe KD, Campbell KA, Sauter PK, Coleman J, et al. Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma—part 3: update on 5-year survival. J Gastrointest Surg. 2005;9:1191–204; discussion 204–6.PubMedCrossRef Riall TS, Cameron JL, Lillemoe KD, Campbell KA, Sauter PK, Coleman J, et al. Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma—part 3: update on 5-year survival. J Gastrointest Surg. 2005;9:1191–204; discussion 204–6.PubMedCrossRef
4.
go back to reference Pawlik TM, Abdalla EK, Barnett CC,, Ahmad SA, Cleary KR, Vauthey JN, et al. Feasibility of a randomized trial of extended lymphadenectomy for pancreatic cancer. Arch Surg. 2005;140:584–9; discussion 9–91.PubMedCrossRef Pawlik TM, Abdalla EK, Barnett CC,, Ahmad SA, Cleary KR, Vauthey JN, et al. Feasibility of a randomized trial of extended lymphadenectomy for pancreatic cancer. Arch Surg. 2005;140:584–9; discussion 9–91.PubMedCrossRef
5.
go back to reference Raut CP, Tseng JF, Sun CC, Wang H, Wolff RA, Crane CH, et al. Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg. 2007;246:52–60.PubMedCrossRef Raut CP, Tseng JF, Sun CC, Wang H, Wolff RA, Crane CH, et al. Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg. 2007;246:52–60.PubMedCrossRef
6.
go back to reference Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res. 2004;10:6897–6904.PubMedCrossRef Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res. 2004;10:6897–6904.PubMedCrossRef
7.
go back to reference Husemann Y, Geigl JB, Schubert F, Musiani P, Meyer M, Burghart E, et al. Systemic spread is an early step in breast cancer. Cancer Cell. 2008;13:58–68.PubMedCrossRef Husemann Y, Geigl JB, Schubert F, Musiani P, Meyer M, Burghart E, et al. Systemic spread is an early step in breast cancer. Cancer Cell. 2008;13:58–68.PubMedCrossRef
8.
go back to reference Tseng JF, Raut CP, Lee JE, Pisters PW, Vauthey JN, Abdalla EK, et al. Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg. 2004;8:935–49.PubMedCrossRef Tseng JF, Raut CP, Lee JE, Pisters PW, Vauthey JN, Abdalla EK, et al. Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg. 2004;8:935–49.PubMedCrossRef
9.
go back to reference Katz MHG, Fleming JB, Pisters PWT, Lee JE, Evans DB. Anatomy of the superior mesenteric vein with special reference to the surgical management of first-order branch involvement at pancreaticoduodenectomy. Ann Surg. 2008;248(6):1098–102.PubMedCrossRef Katz MHG, Fleming JB, Pisters PWT, Lee JE, Evans DB. Anatomy of the superior mesenteric vein with special reference to the surgical management of first-order branch involvement at pancreaticoduodenectomy. Ann Surg. 2008;248(6):1098–102.PubMedCrossRef
10.
go back to reference Exocrine pancreas. In: Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, et al., editors. AJCC cancer staging manual. New York: Springer; 2002. p. 157–64. Exocrine pancreas. In: Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, et al., editors. AJCC cancer staging manual. New York: Springer; 2002. p. 157–64.
Metadata
Title
Pancreaticoduodenectomy and Vascular Resection: Persistent Controversy and Current Recommendations
Authors
Kathleen Christians, MD
Douglas B. Evans, MD
Publication date
01-04-2009
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 4/2009
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-009-0322-y

Other articles of this Issue 4/2009

Annals of Surgical Oncology 4/2009 Go to the issue